BACKGROUND: Head and neck squamous cell carcinomas (HNSCCs) have devastating morbidity rates with mortality mainly because of metastasis. METHODS: Multiplex enzyme-linked immunosorbent assay (ELISA) to assay a variety of cytokine levels secreted by a panel of stage-specific and anatomic site-specific primary, and recurrent and metastatic University of Michigan-HNSCC cell lines over a 72-hour time course. RESULTS: Conditioned medium from metastatic or recurrent HNSCC showed significantly higher amounts of interleukin (IL)-6, IL-6 receptor, tumor growth factor-beta (TGF-β) and vascular endothelial growth factor (VEGF) than nonmetastatic cells or normal oral keratinocytes. Tumor necrosis factor (TNF) was only secreted by stage IV, metastatic, or recurrence-derived cell lines. CONCLUSION: The cytokine profile of cultured HNSCC cells suggests that high levels of IL-6 and IL-6R, TGF-β, and VEGF are significantly related with their metastatogenic potential and provide rationale for determining if serum testing for a combination of these 4 soluble factors could be of predictive value for the HNSCC tumor progression and clinical outcome.
BACKGROUND: Head and neck squamous cell carcinomas (HNSCCs) have devastating morbidity rates with mortality mainly because of metastasis. METHODS: Multiplex enzyme-linked immunosorbent assay (ELISA) to assay a variety of cytokine levels secreted by a panel of stage-specific and anatomic site-specific primary, and recurrent and metastatic University of Michigan-HNSCC cell lines over a 72-hour time course. RESULTS: Conditioned medium from metastatic or recurrent HNSCC showed significantly higher amounts of interleukin (IL)-6, IL-6 receptor, tumor growth factor-beta (TGF-β) and vascular endothelial growth factor (VEGF) than nonmetastatic cells or normal oral keratinocytes. Tumor necrosis factor (TNF) was only secreted by stage IV, metastatic, or recurrence-derived cell lines. CONCLUSION: The cytokine profile of cultured HNSCC cells suggests that high levels of IL-6 and IL-6R, TGF-β, and VEGF are significantly related with their metastatogenic potential and provide rationale for determining if serum testing for a combination of these 4 soluble factors could be of predictive value for the HNSCC tumor progression and clinical outcome.
Authors: Clint Allen; Sonia Duffy; Theodoros Teknos; Mozaffarul Islam; Zhong Chen; Paul S Albert; Gregory Wolf; Carter Van Waes Journal: Clin Cancer Res Date: 2007-06-01 Impact factor: 12.531
Authors: Josiah Ochieng; Gladys N Nangami; Olugbemiga Ogunkua; Isabelle R Miousse; Igor Koturbash; Valerie Odero-Marah; Lisa J McCawley; Pratima Nangia-Makker; Nuzhat Ahmed; Yunus Luqmani; Zhenbang Chen; Silvana Papagerakis; Gregory T Wolf; Chenfang Dong; Binhua P Zhou; Dustin G Brown; Anna Maria Colacci; Roslida A Hamid; Chiara Mondello; Jayadev Raju; Elizabeth P Ryan; Jordan Woodrick; A Ivana Scovassi; Neetu Singh; Monica Vaccari; Rabindra Roy; Stefano Forte; Lorenzo Memeo; Hosni K Salem; Amedeo Amedei; Rabeah Al-Temaimi; Fahd Al-Mulla; William H Bisson; Sakina E Eltom Journal: Carcinogenesis Date: 2015-06 Impact factor: 4.944
Authors: Petros Papagerakis; Giuseppe Pannone; L I Zheng; Maria Athanassiou-Papaefthymiou; Yashuo Yamakoshi; Howard Stan McGuff; Omar Shkeir; Konstantinos Ghirtis; Silvana Papagerakis Journal: Anticancer Res Date: 2015-04 Impact factor: 2.480
Authors: Leticia Bagan; Guillermo T Sáez; M Carmen Tormos; Carlos Labaig-Rueda; Judith Murillo-Cortes; Jose V Bagan Journal: Clin Oral Investig Date: 2015-08-09 Impact factor: 3.573
Authors: Michael J Czerwinski; Vincenzo Desiderio; Omar Shkeir; Petros Papagerakis; Martian C Lapadatescu; John H Owen; Maria Athanassiou-Papaefthymiou; Li Zheng; Gianpaolo Papaccio; Mark E Prince; Silvana Papagerakis Journal: Otolaryngol Head Neck Surg Date: 2013-04-04 Impact factor: 3.497
Authors: Fereshteh Nazari; Alexander T Pearson; Jacques Eduardo Nör; Trachette L Jackson Journal: PLoS Comput Biol Date: 2018-01-19 Impact factor: 4.475
Authors: Amber M Bates; Maria Paula Gomez Hernandez; Emily A Lanzel; Fang Qian; Kim A Brogden Journal: Transl Cancer Res Date: 2018-06 Impact factor: 1.241